Anselamimab Trial Failed to Meet Primary Endpoint
The drug failed to improve outcomes in a broad group of patients with advanced cardiac-stage light-chain amyloidosis.
Updated on Sept. 22, 2026 in Heart Disease
Live Poll
Should clinical trial success be measured by results for specific genetic subgroups rather than entire populations?
A large-scale clinical program evaluating the experimental drug anselamimab has failed to reach its primary composite endpoint for patients with light-chain amyloidosis. While the trial did not show overall success, researchers observed potential benefits for a specific subgroup with kappa light-chain disease.
Why it matters
This research sought to determine if anselamimab could improve survival in patients with light-chain amyloidosis by physically removing existing protein fibrils. The findings highlight the complex nature of this condition and the need for precision medicine when targeting specific protein types.
The CARES program of two double-blind trials randomized patients to receive chemotherapy plus anselamimab or a placebo. While the total population failed to reach the primary endpoint, the kappa light-chain subgroup saw a 62% reduction in mortality and 71% reduction in hospitalization risk.
The details
The experimental treatment involves administering anselamimab at 1000 mg/m weekly for four weeks, followed by maintenance doses every two weeks. The therapy is designed to target and clear existing protein fibrils that infiltrate cardiac tissue, which causes the organ damage seen in light-chain amyloidosis. Grade 3 adverse events occurred in 80.4% of patients receiving the drug, a rate similar to the 84.3% observed in the placebo arm.
Timeline
The clinical research findings were presented in September 2026 at the SOHO meeting.
Health Landscape
The CARES clinical program sits at the center of ongoing efforts to treat light-chain amyloidosis by directly removing protein deposits. These results suggest that future clinical approaches may need to shift toward subtype-specific strategies to achieve meaningful improvements in cardiac outcomes.
Patients with light-chain amyloidosis should discuss these findings with their cardiologist to understand how current treatment regimens are being evaluated. It is particularly important to ask whether testing has identified a specific light-chain subtype, as this may influence future care conversations.
The takeaway
While the broad CARES program did not meet its primary goals, the significant reduction in mortality and hospitalization for those with kappa light-chain amyloidosis marks a potential path forward. Patients should confirm their specific amyloidosis subtype with their oncology or cardiology team.
Further reading
Learn more about the latest research and clinical standards for Heart Disease.
Source note: This article includes information reported by Medscape.
Live Poll
Should clinical trial success be measured by results for specific genetic subgroups rather than entire populations?
